This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Theses and Dissertations
This collection contains theses and dissertations of graduate students of the University of Alberta. The collection contains a very large number of theses electronically available that were granted from 1947 to 2009, 90% of theses granted from 2009-2014, and 100% of theses granted from April 2014 to the present (as long as the theses are not under temporary embargo by agreement with the Faculty of Graduate and Postdoctoral Studies). IMPORTANT NOTE: To conduct a comprehensive search of all UofA theses granted and in University of Alberta Libraries collections, search the library catalogue at www.library.ualberta.ca - you may search by Author, Title, Keyword, or search by Department.
To retrieve all theses and dissertations associated with a specific department from the library catalogue, choose 'Advanced' and keyword search "university of alberta dept of english" OR "university of alberta department of english" (for example). Past graduates who wish to have their thesis or dissertation added to this collection can contact us at erahelp@ualberta.ca.
Items in this Collection
- 2Carboplatin
- 1Audiology
- 1Childhood cancer
- 1Childhood cancer survivors
- 1Cisplatin
- 1Cochlear radiation
-
Fall 2019
The development of efficacious anticancer therapies has significantly improved the prognosis of childhood cancer patients at the price of predisposing survivors to extensive chronic health problems. Although not fatal, reducing treatment-related hearing loss (ototoxicity) among childhood cancer...
-
Novel mechanisms of carboplatin resistance in epithelial ovarian cancer and their therapeutic potential
DownloadFall 2015
Ovarian cancer is the fifth leading cause of cancer-related mortality in women. Epithelial ovarian cancer (EOC) constitutes approximately 90% of all ovarian malignancies. Platinum-based compounds have been used to treat EOC, with carboplatin currently being used as a first-line therapeutic agent...